Clinical factors associated with a Candida albicans Germ Tube Antibody positive test in Intensive Care Unit patients

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Pemán, Javier ^a   Zaragoza, Rafael ^b   Quindós, Guillermo ^c   Alkorta, Miriam ^d   Cuétara, María S ^e   Camarena, Juan J ^b   Ramírez, Paula ^a   Giménez, María J ^a   Martín Mazuelos, Estrella ^f   Linares Sicilia, María J ^g   Pontón, José ^c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d HOSPITAL DE ZUMÁRRAGA   (Spain)

^e HOSPITAL SEVERO OCHOA   (Spain)

^f Department of Microbiology Hospital NS de Valme ^*  (Spain)

^g Universidad de Cordoba   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE; FUNGUS ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA ALBICANS GERM TUBE ANTIBODY TEST; CANDIDIASIS; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIAGNOSTIC TEST; DISEASE MARKER; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MOUSE; MULTICENTER STUDY; NONHUMAN; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK FACTOR; SPAIN; SURGERY; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; IMMUNOASSAY; IMMUNOLOGY; MALE; METHODOLOGY; MIDDLE AGED; MYCOLOGY;

AGED; AGED, 80 AND OVER; ANTIBODIES, FUNGAL; CANDIDA ALBICANS; CANDIDIASIS; COHORT STUDIES; CRITICAL ILLNESS; FEMALE; HUMANS; IMMUNOASSAY; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MYCOLOGY; PROSPECTIVE STUDIES; SPAIN;

EID: 79952335963     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-60     Document Type: Article

References (39)

1. Zaragoza R, Pemán J. Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy. Rev Iberoam Micol 2006, 23:59-63. 10.1016/S1130-1406(06)70014-6, 16854178.
2. Zaragoza R, Pemán J. Diagnostic and therapeutic approach to fungal infections in critical care settings: different options but the same strategy. J Invasive Fungal Infect 2007, 1:50-58.
3. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029. 10.1056/NEJMoa021585, 12490683.
4. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442. 10.1016/S0140-6736(05)67490-9, 16243088.
5. Pachl J, Svoboda P, Jacobs F, Vandewoude K, van der HB, Spronk P, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006, 42:1404-1413. 10.1086/503428, 16619152.
6. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482. 10.1056/NEJMoa066906, 17568028.
7. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527. 10.1016/S0140-6736(07)60605-9, 17482982.
8. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645. 10.1128/AAC.49.9.3640-3645.2005, 1195428, 16127033.
9. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31. 10.1086/504810, 16758414.
10. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31:2742-2751. 10.1097/01.CCM.0000098031.24329.10, 14668610.
11. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007, 60:613-618. 10.1093/jac/dkm212, 17576697.
12. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34:730-737.
13. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1 -- 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659. 10.1086/432470, 16080087.
14. Yera H, Sendid B, Francois N, Camus D, Poulain D. Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis. Eur J Clin Microbiol Infect Dis 2001, 20:864-870. 10.1007/s100960100629, 11837637.
15. Quindós G, Moragues MD, Pontón J. Is there a role for antibody testing in the diagnosis of invasive candidiasis?. Rev Iberoam Micol 2004, 21:10-14.
16. Moragues MD, Ortiz N, Iruretagoyena JR, Garcia-Ruiz JC, Amutio E, Rojas A, et al. Evaluation of a new commercial test (Candida albicans IFA IgG) for the serodiagnosis of invasive candidiasis. Enferm Infecc Microbiol Clin 2004, 22:83-88.
17. Quindós G, Pontón J, Cisterna R. Detection of antibodies to Candida albicans germ-tubes in the serodiagnosis of systemic candidosis. Eur J Clin Microbiol Infect Dis 1987, 6:142-146.
18. Garcia-Ruiz JC, del Carmen AM, Regulez P, Quindós G, Alvarez A, Pontón J. Detection of antibodies to Candida albicans germ tubes for diagnosis and therapeutic monitoring of invasive candidiasis in patients with hematologic malignancies. J Clin Microbiol 1997, 35:3284-3287. 230163, 9399535.
19. Zaragoza R, Pemán J, Quindós G, Iruretagoyena JR, Cuetara M, Ramirez P, et al. Clinical significance of Candida albicans germ tube antibody detection in critically ill patients. Clin Microbiol Infect 2009, 15:592-595. 10.1111/j.1469-0691.2009.02794.x, 19438621.
20. Zaragoza R, Pemán J, Quindós G, Iruretagoyena JR, Cuétara MS, Ramirez P, et al. Kinetic Patterns of Candida albicans Germ Tube Antibody (CAGTA) in Critically Ill Patients: Influence on Mortality. Clin Vaccine Immunol 2009, 16:1527-1528. 10.1128/CVI.00183-09, 2756852, 19675223.
21. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994, 220:751-758. 10.1097/00000658-199412000-00008, 1234477, 7986142.
22. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003, 3:772-785. 10.1016/S1473-3099(03)00831-4, 14652203.
23. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004, 32:2443-2449. 10.1097/01.CCM.0000147726.62304.7F, 15599149.
24. Bikandi J, San Millán R, Regulez P, Moragues MD, Quindós G, Pontón J. Detection of antibodies to Candida albicans germ tubes during experimental infections by different Candida species. Clin Diagn Lab Immunol 1998, 5:369-374. 104526, 9605993.
25. Zaragoza R, Pemán J, Salavert M, Viudes A, Sole A, Jarque I, et al. Multidisciplinary approach to the treatment of invasive fungal infections. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?. Ther Clin Risk Management 2008, 4:1-20.
26. Pontón J, Jones JM. Identification of two germ tube specific cell wall antigens of Candida albicans. Infect Immun 1986, 54:864-868. 260250, 2430889.
27. Pontón J, Quindós G, Arilla MC, Mackenzie DW. Simplified adsorption method for detection of antibodies to Candida albicans germ tubes. J Clin Microbiol 1994, 32:217-219. 263001, 8126184.
28. Quindós G, Alvarez M, Regulez P, Pontón J, Cisterna R. Diagnosis of systemic candidiasis in parenteral drug addicts by detection of antimycelial antibodies. Med Clin (Barc) 1988, 90:451-455.
29. Iruretagoyena JR, Regulez P, Quindós G, Pontón J. Antibodies to Candida albicans germ tubes in two intensive care patients with invasive candidiasis. Rev Iberoam Micol 2000, 17:93-96.
30. Quindós G, Pontón J, Cisterna R, Mackenzie DW. Value of detection of antibodies to Candida albicans germ tube in the diagnosis of systemic candidosis. Eur J Clin Microbiol Infect Dis 1990, 9:178-183.
31. Salesa R, Moragues MD, Sota R, Pemán J, Quindós G, Pontón J. Specific antibody response in a patient with Candida dubliniensis fungemia. Rev Iberoam Micol 2001, 18:42-44.
32. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993, 17:103-109. 10.1016/0732-8893(93)90020-8, 8243032.
33. Alvarez-Lerma F, Palomar M, León C, Olaechea P, Cerda E, Bermejo B. Indications for antifungal treatment in intensive care unit patients. Enferm Infecc Microbiol Clin 2004, 22:279-285. 10.1157/13059821, 15207119.
34. Kami M, Machida U, Okuzumi K, Matsumura T, Mori SS, Hori A, et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol 2002, 117:40-46. 10.1046/j.1365-2141.2002.03414.x, 11918531.
35. Nolla-Salas J, Sitges-Serra A, León-Gil C, Martinez-Gonzalez J, León-Regidor MA, Ibanez-Lucia P, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997, 23:23-30. 10.1007/s001340050286, 9037636.
36. Ibañez-Nolla J, Nolla-Salas M, León MA, Garcia F, Marrugat J, Soria G, et al. Early diagnosis of candidiasis in non-neutropenic critically ill patients. J Infect 2004, 48:181-192.
37. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005, 43:235-243. 10.1080/13693780410001731619, 16010850.
38. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007, 26:271-276. 10.1007/s10096-007-0270-z, 17333081.
39. Charles PE. Multifocal Candida species colonization as a trigger for early antifungal therapy in critically ill patients: what about other risk factors for fungal infection?. Crit Care Med 2006, 34:913-914. 10.1097/01.CCM.0000202435.98240.ED, 16505683.